CHMP Recommends Galderma’s Nemolizumab for Atopic Dermatitis and Prurigo Nodularis
Galderma has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the marketing authorization of nemolizumab for the treatment of both atopic dermatitis and prurigo nodularis in the European…
AI Compliance Breakthrough Wins Klick Prize, Highlighting Industry Trends
Klick Health has announced the Grand Prize winner of the $1,000,000 Klick Prize, following the submission of several hundred AI ideas from employees for life sciences clients. The company shared key insights from its year-long internal contest and discussed the…
Biotech Nintx Secures US$ 10 Million to Develop Medicines from Brazilian Biodiversity
Nintx (Next Innovative Therapeutics), a Brazilian biotech company focused on developing treatments for multifactorial diseases using Brazil’s rich biodiversity, has raised an additional US$ 10 million following a US$ 3 million seed investment in 2022. This new funding will support…
Sensome Reveals Data on Clot-Sensing Guidewire for Peripheral Artery Disease Treatment
Sensome, a leader in microsensing technology for real-time intra-operative tissue analysis, has announced promising results from two studies of its Clotild® Smart Guidewire System. The system effectively identified “fresh” clot—thrombus rich in red blood cells (RBCs)—in peripheral artery disease (PAD)…
PHC LiCellMo Wins 2024 Innovation Award from The Analytical Scientist
PHC Corporation’s Biomedical Division (Headquarters: Chiyoda-ku, Tokyo, Japan; President: Nobuaki Nakamura) has been awarded the 2024 Innovation Award by The Analytical Scientist for its live-cell metabolic analyzer, LiCellMo™. Launched in Japan in September and in select regions, including the US,…
Upbound to Acquire Brigit for Up to $460 Million
Upbound Group, Inc. (NASDAQ: UPBD), a leader in accessible and inclusive financial products powered by technology and data, has announced a definitive agreement to acquire Brigit, a top financial health technology company, for up to $460 million. The deal will…
Corcept Announces Positive CATALYST Trial Results
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company focused on developing medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating cortisol, announced today that the primary endpoint was met in the treatment phase of CATALYST. This randomized,…
Parse Biosciences Launches Mouse BCR for Antibody Discovery
Parse Biosciences, a leader in scalable single-cell sequencing solutions, today announced the expansion of its Evercode BCR™ product line to support mouse applications. The new kits allow researchers to profile the mouse BCR repertoire alongside whole transcriptome data for millions…
Lyra Forecast: Rising Mental Health Claims for Youth and Severe Needs
Lyra Health, a leader in Workforce Mental Health solutions for employers, today shared early insights from its 2025 Workforce Mental Health Trends Forecast. The fifth annual study found that 81% of benefits leaders are increasingly worried about the rising levels…
Repare Therapeutics Reports Positive Results from MYTHIC Phase 1 Trial
Repare Therapeutics Inc. (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced positive data from its MYTHIC Phase 1 gynecologic expansion clinical trial. The trial evaluated the combination of lunresertib and camonsertib (Lunre+Camo) at the recommended Phase 2 dose (RP2D)…
NanoVibronix Secures $12M Commitment for PainShield with Distribution Agreement Extension
NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company specializing in surface acoustic wave (SAW) technology, has announced the renewal of its exclusive distribution agreement with Ultra Pain Products, Inc. (UPPI) for the distribution of the PainShield device. The five-year extension…
SamanTree Medical Reports 67% Reduction in Reoperation Rates for Breast-Conserving Surgery at 2024 SABCS
SamanTree Medical, a leader in oncologic surgical imaging innovation, announced promising results from the SHIELD study, to be presented at the 2024 San Antonio Breast Cancer Symposium (SABCS) on Dec. 12. The findings reveal that the Histolog® Scanner, a confocal…